Logzzi et al. reported that specific prostate-specific antigen (PSA) exosomes efficiently differentiated between prostate cancer (PC) and non-PC patients (benign prostatic hyperplasia (BPH) and healthy controls), outperforming the traditional serum PSA test. Here, KLK3 is linked to benign prostatic hyperplasia.